Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 390
- Registration Number
- NCT00003913
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-12-23
- Target Recruit Count
- 2000
- Registration Number
- NCT00004128
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-10-07
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 28
- Registration Number
- NCT00006246
- Locations
- 🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-12-10
- Target Recruit Count
- 125
- Registration Number
- NCT00005797
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
- Conditions
- Interventions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00043810
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
- Conditions
- First Posted Date
- 2002-06-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT00040469
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2013-05-01
- Target Recruit Count
- 2
- Registration Number
- NCT00034528
- Locations
- 🇺🇸
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, Massachusetts, United States
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
- Conditions
- First Posted Date
- 2002-01-11
- Last Posted Date
- 2016-07-29
- Target Recruit Count
- 30
- Registration Number
- NCT00029380
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
- Conditions
- Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable ImmunodeficiencyGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeChronic Granulomatous Disease
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00006054
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.